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ABSTRACT
Myxoedema coma is a sporadic life-threatening complication of severe hypothyroidism with high mortality. Altered mental status and hypothermia 
are the main symptoms of myxoedema coma. Apart from that, hypoxia, bradycardia, hypotension, anemia, and hyponatremia would be present. Few 
patients present comatose with severe myxoedema. Presenting coma may mislead the diagnosis of this condition. A female patient presented with 
fever, breathlessness, and disorientation was admitted. First diagnosed to have electrolyte imbalance and treatment was started accordingly. The 
patient did not show much of an improvement, and it took a day to identify the presence of severe hypothyroidism. Treating hypothyroidism resulted 
in an advance in the patient condition. Patients’ previous history of hypothyroidism was not informed during admission. It is always tough to diagnose 
myxoedema coma when the patients’ previous history of hypothyroidism is unknown. Hence, it is still essential to have hypothyroidism in mind while 
treating patients with comatose. This case has been reported to alert physicians in diagnosing myxoedema coma patients and to proceed with the 
treatment at the earliest.
Keywords: Myxoedema coma, Hypothyroidism, Hyponatremia.
BACKGROUND
Myxoedema coma is a scarce form of severe hypothyroidism with very 
high mortality of 50–60% [1]. When hypothyroidism has not been 
treated properly, it will result in many physiological decompensations 
such as hypoxia, bradycardia, hypotension, anemia, hyponatremia, 
and hypoventilation [2-5]. Drugs, infection, hypothermia, and other 
systemic condition act as the triggering point for this condition in 
patients with severe untreated hypothyroidism [6].
CASE REPORT
A 51-year-old female was brought to Sree Balaji Medical College and 
Hospital casualty with complaints of difficulty to breath, bilateral leg 
swelling, fever for 5 days, and drowsiness for 1 day. Patient did not 
have previous history of medical illness such as diabetes mellitus, 
hypertension, hypothyroidism, and seizure disorder. Her previous drug 
history (if any) was not known.
Her general examination, the patient was drowsy, obeying simple 
commands, dyspneic at rest, mild pallor and facial puffiness present, 
bilateral pitting pedal edema noticed, peripheries were very cold to 
touch with a capillary refill of more than 5 s, no clubbing, no cyanosis, 
and no peripheral lymphadenopathy. BP – 90/60 mmHg, pulse rate – 
46/min, temperature – 96°F, SpO2 - 93%, and inspection of the cervical 
region showed no enlarged thyroid gland/goiter.
Systemic examination: Cardiovascular system – S1S2 normal, respiratory 
system – bilateral air entry present, abdomen – soft, no organomegaly, 
central nervous system – no sensory and motor deficits, and Glasgow 
Coma Scale – 12/15. On admission, she was found to have decreased 
sodium levels and treated accordingly. Her condition worsened after 12 
h of admission, she was shifted to intensive care unit where orotracheal 
intubation done and she was supported by mechanical ventilation. She 
was diagnosed with myxoedema coma with severe hypothyroidism and 
electrolyte imbalance (Table 1).
OTHER REPORTS
•	 Arterial blood gas – analysis showed respiratory acidosis
•	 Electrocardiogram – bradycardia
•	 Chest X-ray – mild pericardial effusion
•	 Ultrasound abdomen-Normal study
•	 Computed tomography brain – normal study.









This patient was initially treated for electrolyte imbalance with in vitro 
fertilization – 3% NS. After one of admission, she was found to have 
severe hypothyroidism with many physiological decompensations. 
Two units of packed cells were transfused. Sodium and potassium 
replacement were given. Intravenous (IV) antibiotics were given. This 
patient’s serum thyroid-stimulating hormone (TSH) was high and her 
free T3 was very low, which indicates primary hypothyroidism rather 
than pituitary dysfunction. There was no available IV thyroxine (in 
hand), and the patient was administered higher dose (double dose) of 
oral regimen.
Thyroxine (T4) was administered through Ryle’s tube as a bolus dose 
of 300 µg followed by 300 µg the next 3 days. IV hydrocortisone was 
administered as a bolus dose of 100 mg followed by 50 mg 4 times 
a day. The patient condition improved. She was extubated. She was 
transferred to general medicine female ward from where she was 
discharged. She was advised to come for periodic check-up and to take 
hypothyroid drugs regularly.
DISCUSSION
Untreated severe hypothyroidism results in myxoedema coma, 
which is a life-threatening condition causing many physiological 
decompensations, including mental changes [1,2,4,7]. Elderly women 
with long-standing, undiagnosed, or undertreated hypothyroidism 
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were commonly affected by myxoedema coma whose present condition 
is triggered by significant additional stress, such as infection, a systemic 
disease, certain medications, and exposure to a cold environment 
[8]. The clinical features of myxoedema coma are altered level of 
consciousness, bradycardia, hypothermia, hypoglycemia, hypotension, 
hyponatremia, concurrent (precipitating) illness, and anemia. This 
patient was found to have almost all clinical features of myxoedema 
coma. Coexisting adrenal insufficiency in hypothyroidism causes 
hypoglycemia. Hyponatremia, which is the very common presentation 
in myxoedema coma is due to reduced levels of Na+/K+ATPase, 
decreased sodium reabsorption, and impaired free water excretion. 
There are high chances of cardiac disease in hypothyroid patients 
with raised inflammation [9-14]. This patient had hypotension and 
severe bradycardia, reduced cardiac contractility which are common 
in hypothyroidism. Thyroid hormone replacement reverses these 
heart changes [9]. Hypoventilation and respiratory acidosis are due to 
respiratory depression. Furthermore, macroglossia or myxoedema of 
the larynx can lead to airway obstruction. Ventilatory support is needed 
in some patients, and respiratory depression can be reversed after 3–6 
months of treatment [4]. Poor prognostic factors include persistent 
hypothermia that is unresponsive to 72 h of therapy, advanced age, 
bradycardia (<44 beats/min), sepsis, myocardial infarction, and 
hypotension. Predictive values of survival are the patient’s level of 
consciousness at admission and his/her score on the Glasgow Coma 
Scale and on the acute physiology and chronic health evaluation II [10]. 
Three different regimens for treating myxoedema coma have been 
suggested [11]: (1) IV or oral T4, (2) IV T3, or (3) a combination of T4 
and T3. It is advisable to give T4 intravenously due to unpredictability 
of oral route absorption [12].
This patient’s serum TSH was high and her free T3 was very low, which 
indicates primary hypothyroidism rather than pituitary dysfunction. 
There was no available IV thyroxine, so the patient was administered 
higher dose (double dose) of oral regimen.
Thyroxine (T4) was administered through Ryle’s tube as a bolus dose 
of 300 µg followed by 300 µg the next 3 days. IV hydrocortisone was 
administered as a bolus dose of 100 mg followed by 50 mg 4 times a 
day. It is generally advised to treat patients with myxoedema crisis with 
steroids because of possibility of coexistent adrenal insufficiency and 
also because thyroid hormone therapy increases cortisol clearance 
from the body. Apart from T4 and steroid administration, ventilatory 
support, IV fluids/vasopressors to correct hypotension, passive 
rewarming, correction of hypoglycemia, correction of hyponatremia, 
correction of anemia, and treatment of underlying infection were also 
taken care of.
CONCLUSION
Myxoedema coma is a rare but a very important medical emergency with 
an increased death rate. Correct diagnosis and early thyroid hormone 
replacement are required. In case of unavailability of laboratory results, 
glucocorticoid administration is the main drug in the treatment of 
hypothyroidism. Supportive measures are of highly important in the 
treatment of myxoedema coma.
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